Patient perspectives on testing for clonal hematopoiesis of indeterminate potential

Tal Sella, Geoffrey G. Fell, Peter G. Miller, Christopher J. Gibson, Shoshana M. Rosenberg, Craig Snow, Daniel G. Stover, Kathryn J. Ruddy, Jeffrey M. Peppercorn, Lidia Schapira, Virginia F. Borges, Steven E. Come, Ellen Warner, Elizabeth Frank, Donna S. Neuberg, Benjamin L. Ebert, Ann H. Partridge

Research output: Contribution to journalArticlepeer-review


Clonal hematopoiesis of indeterminate potential (CHIP), an emerging biomarker for personalized risk-directed interventions, is increased in cancer survivors. However, little is known about patient preferences for CHIP testing. We surveyed participants in a prospective cohort study of young women with breast cancer (BC). The emailed survey included an introduction to CHIP and a vignette eliciting participants’ preferences for CHIP testing, considering sequentially: population-based 10-year risk of BC recurrence, hematologic malignancy, and heart disease; increased CHIP-associated risks; current CHIP management; dedicated CHIP clinic; and hypothetical CHIP treatment. Preference changes were evaluated using the McNemar test. The survey response rate was 82.2% (528/642). Median age at time of survey was 46 years and median time from diagnosis was 108 months. Only 5.9% had prior knowledge of CHIP. After vignette presentation, most survivors (87.1%) recommended CHIP testing for the vignette patient. Presented next with CHIP-independent, population-based risks, 11.1% shifted their preference from testing to not testing. After receiving information about CHIP-associated risks, an additional 10.1% shifted their preference to testing. Preference for testing increased if vignette patient was offered a CHIP clinic or hypothetical CHIP treatment, with 7.2% and 14.1% switching preferences toward testing, respectively. Finally, 75.8% of participants desired CHIP testing for themselves. Among participants, 28.2% reported that learning about CHIP caused at least moderate anxiety. Most young survivors favored CHIP testing, with preferences influenced by risk presentation and potential management strategies. Our findings highlight the importance of risk communication and psychosocial support when considering biomarkers for future risk in cancer survivors.

Original languageEnglish (US)
Pages (from-to)6151-6160
Number of pages10
JournalBlood Advances
Issue number24
StatePublished - Dec 27 2022

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Patient perspectives on testing for clonal hematopoiesis of indeterminate potential'. Together they form a unique fingerprint.

Cite this